Michael Blaese

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.3kcitations36works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(10), Immunotherapy and Immune Responses(9), Immune Cell Function and Interaction(8), RNA Interference and Gene Delivery(7), Immunodeficiency and Autoimmune Disorders(4)

Publications36 total

IDF Medical Advisory Committee Resolution on Product Choice for Immunoglobulin Replacement Therapy
2011
Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus—mediated tumor complementary DNA
Journal of neurosurgery·2002· 24 cited
Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus—mediated interleukin-12
Journal of neurosurgery·2002· 52 cited
Mode of Action of RNA/DNA Oligonucleotides
CHEST Journal·2002· 27 cited
Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus
Cancer Gene Therapy·2001· 62 cited
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus—mediated complementary DNA
Journal of neurosurgery·2001· 68 cited
Primary Sclerosing Cholangitis in Wiskott–Aldrich Syndrome
Journal of Pediatric Gastroenterology and Nutrition·2001
Primary Sclerosing Cholangitis in Wiskott–Aldrich Syndrome
Journal of Pediatric Gastroenterology and Nutrition·2001· 7 cited
Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12
Neurosurgical FOCUS·2000· 21 citedOpen Access
GENE THERAPY FOR INHERITED AND ACQUIRED IMMUNODEFICIENCY DISEASES 1
Pediatric Research·1997Open Access
High-Efficiency Transduction of Freshly Isolated Human Tumor Cells Using Adenoviral Interleukin-2 Vectors
Human Gene Therapy·1996· 31 cited
Vectors in cancer therapy: how will they deliver?
PubMed·1995· 58 cited
European school of Oncology position paper. Gene therapy for the medical oncologist
European Journal of Cancer·1995· 8 cited
The Development of Gene Therapy for the Treatment of Cancer
Annals of Surgery·1993· 78 citedOpen Access
Development of Gene Therapy for Immunodeficiency: Adenosine Deaminase Deficiency
Pediatric Research·1993· 82 citedOpen Access
Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Tumor Necrosis Factor (National Institutes of Health)
Human Gene Therapy·1992· 51 cited
Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Interleukin-2 (National Institutes of Health)
Human Gene Therapy·1992· 43 cited
Measurement of Polyclonal Immunoglobulin Synthesis Using the Reverse Plaque Technique
Current Protocols in Immunology·1991
Localization of the gene for the Wiskott-Aldrich syndrome between two flanking markers, TIMP and DXS255, on Xp11.22–Xp11.3
Genomics·1991· 58 cited
Genetic mapping of the Wiskott-Aldrich syndrome with two highly-linked polymorphic DNA markers
Genomics·1988· 59 cited
page 1 of 2Next →

Frequent Co-authors

Ryuya Yamanaka(5), Kleanthis G. Xanthopoulos(5), Jay Ramsey(5), Susan A. Zullo(4), Ryuichi Tanaka(4), Steven A. Rosenberg(3), John R. Yannelli(3), Suzanne L. Topalian(3), Douglas J. Schwartzentruber(3), Jeffrey S. Weber(3), Stephen E. Ettinghausen(3), Carlos A. Martínez(3), W. French Anderson(2), Sau‐Ping Kwan(2), Fred S. Rosen(2), Joost J. Oppenheim(2), Odile Cohen‐Haguenauer(2), Bernd Gänsbacher(2), Brian P. Sorrentino(2), Thierry Velu(2)